FDA Approves Pfizer's Talzenna and Xtandi Combination for Metastatic Hormone-Sensitive Prostate Cancer
The U.S. Food and Drug Administration has approved the combination therapy of Pfizer's (PFE) Talzenna (talazoparib) and Xtandi (enzalutamide) for treating men with metastatic hormone-sensitive prostate cancer (mHSPC). This approval specifically targets patients possessing homologous recombination repair gene mutations (HRRm). The expansion into this earlier stage of metastatic disease represents a significant clinical milestone for Pfizer's oncology portfolio. By addressing the HRRm patient population in an earlier treatment setting, the regimen aims to improve outcomes for men facing progressing prostate cancer before it reaches more advanced stages.